Peringatan Keamanan

There is no information on the LD50 of cholera vaccine.

There have been reports of multiple doses of cholera vaccine being administered several weeks apart. The adverse reactions reported were comparable to those seen after the recommended dose.L39720

Vibrio cholerae CVD 103-HgR strain live antigen

DB14443

biotech approved investigational

Deskripsi

Vibrio cholerae CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against Vibrio cholerae serogroup O1.L12801 Cholera is an acute bacterial disease of the small intestine caused by Vibrio cholerae, which is gram-negative bacteria. Two serogroups of V. cholerae, O1 and O139, are causative agents of epidemic cholera. Serogroup O1 is responsible for the majority of cholera outbreaks.A244494 Cholera outbreaks remain a major global public health problem that mainly affects countries with limited access to clean water, poor hygiene, and proper sanitation; thus, effective vaccines to protect individuals against cholera disease are critical.A244489

The FDA approved the cholera vaccine containing Vibrio cholerae CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera prevention to become available in the U.S.A244494 Vaxchora was later approved by the European Commission in April 2020.L39729 It is indicated for individuals aged two years and older.L12801

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Pharmacokinetic information is not applicable.
Volume Distribusi Pharmacokinetic information is not applicable.
Klirens (Clearance) Pharmacokinetic information is not applicable.

Absorpsi

Pharmacokinetic information is not applicable.

Metabolisme

Pharmacokinetic information is not applicable.

Rute Eliminasi

Pharmacokinetic information is not applicable.

Interaksi Makanan

1 Data
  • 1. Take separate from meals. Avoid food or drink for 60 minutes before and after administration as it may interfere with the protective effect of the vaccine buffer.

Interaksi Obat

771 Data
Flunisolide The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Flunisolide.
Betamethasone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Betamethasone.
Triamcinolone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Triamcinolone.
Prednisone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Prednisone.
Fludrocortisone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Fludrocortisone.
Hydrocortisone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Hydrocortisone.
Prednisolone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Prednisolone.
Methylprednisolone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Methylprednisolone.
Trilostane The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Trilostane.
Budesonide The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Budesonide.
Dexamethasone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dexamethasone.
Corticotropin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Corticotropin.
Cortisone acetate The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cortisone acetate.
Paramethasone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Paramethasone.
Aldosterone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Aldosterone.
Fluprednisolone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Fluprednisolone.
Meprednisone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Meprednisone.
Melengestrol The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Melengestrol.
Deflazacort The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Deflazacort.
Cortivazol The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cortivazol.
Prednylidene The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Prednylidene.
Cloprednol The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cloprednol.
Cortisone The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cortisone.
Etanercept The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Etanercept.
Peginterferon alfa-2a The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Peginterferon alfa-2a.
Interferon alfa-n1 The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon alfa-n1.
Interferon alfa-n3 The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon alfa-n3.
Peginterferon alfa-2b The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Peginterferon alfa-2b.
Anakinra The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Anakinra.
Interferon gamma-1b The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon gamma-1b.
Interferon alfa-2a The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon alfa-2a.
Aldesleukin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Aldesleukin.
Adalimumab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Adalimumab.
Gemtuzumab ozogamicin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Pegaspargase The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Pegaspargase.
Infliximab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Infliximab.
Interferon beta-1b The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon beta-1b.
Interferon alfacon-1 The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon alfacon-1.
Trastuzumab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Trastuzumab.
Rituximab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Rituximab.
Basiliximab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Basiliximab.
Muromonab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Muromonab.
Ibritumomab tiuxetan The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ibritumomab tiuxetan.
Tositumomab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Tositumomab.
Alemtuzumab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Alemtuzumab.
Cyclosporine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cyclosporine.
Alefacept The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Alefacept.
Efalizumab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Efalizumab.
Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon alfa-2b.
Natalizumab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Natalizumab.
Daclizumab The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Daclizumab.
Phenylalanine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Phenylalanine.
Bortezomib The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Bortezomib.
Cladribine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cladribine.
Carmustine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Carmustine.
Amsacrine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Amsacrine.
Bleomycin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Bleomycin.
Chlorambucil The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Chlorambucil.
Raltitrexed The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Raltitrexed.
Mitomycin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Mitomycin.
Bexarotene The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Bexarotene.
Vindesine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Vindesine.
Floxuridine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Floxuridine.
Indomethacin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Indomethacin.
Tioguanine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Tioguanine.
Vinorelbine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Vinorelbine.
Dexrazoxane The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dexrazoxane.
Sorafenib The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Sorafenib.
Streptozocin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Streptozocin.
Trifluridine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Trifluridine.
Gemcitabine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Gemcitabine.
Teniposide The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Teniposide.
Epirubicin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Epirubicin.
Lenalidomide The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Lenalidomide.
Altretamine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Altretamine.
Zidovudine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Zidovudine.
Cisplatin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cisplatin.
Oxaliplatin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Oxaliplatin.
Cyclophosphamide The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cyclophosphamide.
Vincristine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Vincristine.
Fluorouracil The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Fluorouracil.
Propylthiouracil The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Propylthiouracil.
Pentostatin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Pentostatin.
Methotrexate The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Methotrexate.
Carbamazepine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Carbamazepine.
Vinblastine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Vinblastine.
Imatinib The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Imatinib.
Clofarabine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Clofarabine.
Pemetrexed The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Pemetrexed.
Daunorubicin The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Daunorubicin.
Irinotecan The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Irinotecan.
Methimazole The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Methimazole.
Etoposide The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Etoposide.
Sulfasalazine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Sulfasalazine.
Dacarbazine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dacarbazine.
Temozolomide The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Temozolomide.
Penicillamine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Penicillamine.
Mechlorethamine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Mechlorethamine.
Azacitidine The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Azacitidine.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 31879125
    Shaikh H, Lynch J, Kim J, Excler JL: Current and future cholera vaccines. Vaccine. 2020 Feb 29;38 Suppl 1:A118-A126. doi: 10.1016/j.vaccine.2019.12.011. Epub 2019 Dec 24.
  • PMID: 29018300
    Mosley JF 2nd, Smith LL, Brantley P, Locke D, Como M: Vaxchora: The First FDA-Approved Cholera Vaccination in the United States. P T. 2017 Oct;42(10):638-640.

Contoh Produk & Brand

Produk: 7 • International brands: 0
Produk
  • Cholera Vaccine Strain 35a-and 41 8000m/cc
    Suspension • 8000 m / mL • Subcutaneous • Canada • Approved
  • Mutacol
    Powder, for solution • 1000000000 cfu / dose • Oral • Canada • Approved
  • Vaxchora
    Powder, for suspension • 2000000000 unit / dose • Oral • Canada • Approved
  • Vaxchora
    Kit • 1200000000 [CFU]/1 • Oral • US • Approved
  • Vaxchora
    - • 400000000 cells • Oral • EU • Approved
  • Vaxchora
    Kit; Powder, for suspension • 1200000000 [CFU]/1 • Oral • US • Approved
  • Vaxchora
    Kit; Powder, for suspension • 1200000000 [CFU]/1 • Oral • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul